Article Information
History
- September 25, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jerald Sadoff, MD1,$,
- Mathieu Le Gars, PhD1,$,
- Georgi Shukarev, MD1,
- Dirk Heerwegh, PhD2,
- Carla Truyers, PhD2,
- Anne Marit de Groot, PhD1,
- Jeroen Stoop, PhD1,
- Sarah Tete, PhD1,
- Wim Van Damme, MD3,
- Isabel Leroux-Roels, MD4,
- Pieter-Jan Berghmans, MD5,
- Murray Kimmel, MD6,
- Pierre Van Damme, MD8,
- Jan de Hoon, MD, PhD, MsC9,
- Williams Smith, MD10,
- Kathryn E. Stephenson, MD11,
- Dan H. Barouch, MD11,
- Stephen C. De Rosa, MD12,
- Kristen W. Cohen, PhD12,
- M. Juliana McElrath, MD, PhD12,
- Emmanuel Cormier, PhD1,
- Gert Scheper, PhD1,
- Jenny Hendriks, PhD1,
- Frank Struyf, MD2,
- Macaya Douoguih, MD, MPH1,
- Johan Van Hoof, MD1 and
- Hanneke Schuitemaker, PhD1,#
- 1Janssen Vaccines & Prevention, Leiden, The Netherlands
- 2Janssen Research & Development, Beerse, Belgium
- 3Janssen Clinical Pharmacology Unit, Merksem, Belgium
- 4CEVAC - University of Gent, Gent, Belgium
- 5SGS Life Sciences, Antwerp, Belgium
- 6Optimal Research LLC, Melbourne, Florida, USA
- 7OR Peoria, Illinois, USA
- 8Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium
- 9Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
- 10VRG and NOCCR, Knoxville, Tennessee, USA
- 11Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- ↵#corresponding author (hschuite{at}its.jnj.com; +31646270638)
↵$ both authors contributed equally to this study;
Posted September 25, 2020.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
